Cargando…
Short-Term Results of Switch from Conbercept to Bevacizumab or Ranibizumab in Eyes with Persistent Neovascular Age-Related Macular Degeneration
PURPOSE: To study the short-term anatomical and functional outcomes in patients with neovascular age-related macular degeneration (nAMD) who were previously treated with conbercept and switched to ranibizumab or bevacizumab due to persistent activity. METHODS: This retrospective single-arm study inc...
Autores principales: | Wang, Zongyi, Li, Mengyang, Yao, Yuou, Hu, Jie, Tang, Jiyang, Tang, Ran, Piao, Zhenyu, Qu, Jinfeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7508218/ https://www.ncbi.nlm.nih.gov/pubmed/33005448 http://dx.doi.org/10.1155/2020/9340356 |
Ejemplares similares
-
Clinical effectiveness of ranibizumab and conbercept for neovascular age-related macular degeneration: a meta-analysis
por: Wang, Luping, et al.
Publicado: (2018) -
Profile of conbercept in the treatment of neovascular age-related macular degeneration
por: Lu, Xinmin, et al.
Publicado: (2015) -
Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
por: Griffin, David R., et al.
Publicado: (2014) -
Switching from Intravitreal Ranibizumab to Bevacizumab for
Age-Related Macular Degeneration
por: Yamada, Kisaburo, et al.
Publicado: (2011) -
Comparison of efficacy and safety of intravitreal ranibizumab and conbercept before vitrectomy in Chinese proliferative diabetic retinopathy patients: a prospective randomized controlled trial
por: Li, Siying, et al.
Publicado: (2022)